70P Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
ConclusionThe incidence of HPD in our population is concordant with previous report about this topic. As previously described by Ferrara et al, HPD was significantly associated with a high number of metastatic sites before start treatment with ICI and correlated with poor outcomes in patients with advanced NSCLC.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
109P Phase I clinical study for validation of fimaporfin-based photochemical internalisation: A novel technology for enhancing cellular immune responses important for therapeutic effect of peptide-and protein-based vaccines
ConclusionThe photochemically based fimaVacc vaccination technology can be applied safely in humans, and enhances T-cell responses to an HPV peptide vaccine over what is achieved in a control group which received antigen + adjuvant without fimaVacc.Clinical trial identificationNCT02947854.Legal entity responsible for the studyPCI Biotech AS.FundingPCI Biotech AS.DisclosureS. Janetzki: Advisory / Consultancy: PCI Biotech AS. V.T. Edwards: Full / Part-time employment: PCI Biotech AS. H. Olivecrona: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: PCI Biotech AS. S.H. van der Burg: Advi...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
156P T-cell and B-cell intratumoural interactions affect the progression of oropharyngeal squamous cell carcinoma
ConclusionOur results indicate that high abundance of TIL-Bs and high density of direct B cell/CD8+ T cell interactions can preselect patients with excellent prognosis who would profit from less invasive treatment. Furthermore, including B cells as an additional target in novel immunotherapeutic protocols may help to establish the desired sustained antitumor T cell responses in OPSCC patients.Legal entity responsible for the studyKamila Hladikova.FundingSotio a.s.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
145P Immune-competent 3D InSightTM tumour models as novel platform to assess combinatorial biologics therapy
ConclusionOur 3D InSightTM tumour models can be successfully employed for optimal high throughput screening of biologics to unveil the efficacy and anti-tumour properties of immune-targeting therapeutic agents.Legal entity responsible for the studyInSphero.FundingInSphero AG.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
18P The role of circulating neutrophils in the regulation of neoangiogenesis in ovarian cancer
ConclusionThe results obtained indicate an increase in the pro-angiogenic activity of circulating Nph with the progression of OC.References1. Han JM, Gou M, Xiao R. Neutrophils regulate the process of angiogenesis. Sheng Li Xue Bao. 2017 Dec 25;69(6):843--851.2. Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008;100(5):359--372. doi:10.1093/jnci/djn0243. Annunziata CM, Stavnes HT, Kleinberg L, et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovar...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
94O Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data
ConclusionCombination treatment with sitravatinib and tislelizumab was manageable and showed promising antitumor activity in patients with ovarian cancer.Clinical trial identificationNCT03666143.Editorial acknowledgementWriting assistance was provided by Ira Mills, PhD, of Ashfield Healthcare Communications.Legal entity responsible for the studyBeiGene.FundingBeiGene.DisclosureB. Gao: Advisory / Consultancy: Merck Sharp& Dohme. J. Goh: Advisory / Consultancy: Bristol-Myers Squibb, AstraZeneca, and Ipsen; Honoraria (self), Payment for speaking engagements: Merck Sharp& Dohme. B. Markman: Advisory / Consultancy: Nova...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
1O Harmonization and standardization of panel-based tumour mutational burden (TMB) measurement: Real-world results and recommendations of the QuIP study
ConclusionThe QuIP study demonstrated that all TMB panels work under real-world conditions and strongly correlate with WES data, with low variability across sites. Further, we identified both common and panel-specific parameters that influence TMB results in daily practice. Recommendations will be provided that support standardization and enable implementation of TMB testing in routine diagnostics.Legal entity responsible for the studyThe authors.FundingBristol-Myers Squibb, Roche, Illumina, Thermo Fisher, Neo Oncology, Qiagen.DisclosureA. Stenzinger: Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
87P Clinical outcomes of metastasic melanoma patients treated with ipilimumab and nivolumab: A single institution experience
ConclusionIn our cohort, LDH, ECOG and irAEs and no previous treatment were found predictors of response and overall survival. Our median OS and ORR were slighly slower than reported in trials.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureA.M. Arance Fernandez: Honoraria (self): Bristol-Myers Squibb. All other authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
112P Identification of a novel promiscuous anti-NY-ESO-1 immunogenic CD4+ peptide containing a CD8+ T-cell epitope highly present in metastatic gastric cancer responding to combined radiotherapy/anti-PD-1 immunotherapy
ConclusionWe have identified a novel promiscuous anti-NY-ESO-1 immunogenic CD4+ peptide containing the P157-165 HLA-A*02:01/CD8+ epitope that was highly presented at disease resolution and decreased at progression after combined radiotherapy/anti-PD-1 immunotherapy. Our study showed that radiation therapy combined with immune checkpoint blockade would enhance the immune response that correlates with the patient clinical outcome.Legal entity responsible for the studyHamad Medical Corporation.FundingHamad Medical Corporation.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
128TiP VCN-01 plus durvalumab in subjects with recurrent/metastatic head & amp; neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial
AbstractBackgroundVCN-01 is an oncolytic adenovirus with replication restricted to cells with a nonfunctional retinoblastoma pathway. Upon selective replication VCN-01 expresses the matrix remodeling-enzyme hyaluronidase to enhance virus spreading and tumor uptake of different therapeutics, including immune check-point inhibitors. In a phase I performed in pancreatic carcinoma VCN-01 reached tumors after systemic administration and induced CD8-infiltration, tumor inflammation and PD-1/PD-L1 up-regulation. We hypothesize these intratumor effects may help to overcome the observed resistance to Durvalumab and other PD-(L)-1 c...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
111P Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors
ConclusionSo far the vaccine is well tolerated and safe. Neoantigen prediction and immunotherapy manufacturing is feasible within 6 weeks of patient enrolment using the PIONEERTM platform. Preliminary analyses indicate induction of NeoPepVac-specific immune responses.Clinical trial identificationEudraCT: 2018-002892-16.Legal entity responsible for the studyInge Marie Svane.FundingInnovations fonden.DisclosureJ.V. Kringelum: Full / Part-time employment, PhD, Director, Genomic Immuno-Oncology: Evaxion. T. Bogenrieder: Full / Part-time employment, CMO at Evaxion: Evaxion. B. R ønø: Full / Part-time employment, PhD, Director...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
158P Role of iron metabolism in the immunosuppression mediated by myeloid cells in glioblastoma patients
ConclusionOur results show that the connection between iron metabolism and immune response could be exploited from a therapeutic point of view. In particular, HO-1 plays a role in BMDM-induced immunosuppression and could represent a new target to relieve the immunosuppressive microenvironment present in GBM patients.Legal entity responsible for the studyUniversity of Padua.FundingAIRC.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
146P The dynamics between neo-adjuvant treatment and immune responses in human breast cancer
ConclusionNAT provokes changes in immune activities at the tumor site in early BC, with some of these alterations apparently linked to specific treatments. Our ongoing efforts are designed to provide detailed insight into the alterations associated with different NAT modalities and define prognostic biomarkers.Legal entity responsible for the studyThe authors.FundingFRNS, T élévie, Les Amis de l'Institut Bordet, Lambeau Marteau.DisclosureA. Pabois: Full / Part-time employment: Iteos therapeutics. All other authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
44P Evaluation of immune response in young patients with sarcoma treated by dendritic cell-based immunotherapy
ConclusionCirculating cell-based immune markers revealed dose-dependent changes in subtle T-cell subsets during the course of DC treatment. Personalized anti-cancer DC-based ITx stimulates a pre-existing immune response against self-tumor antigens.Clinical trial identificationEudraCT: 2014-003388-39.Legal entity responsible for the studyCzech Ministry of Health.FundingCzech Ministry of Health (Projects LO1413, LM2015090, academic clinical trial).DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
95O The immunoglobulin superfamily receptome defines cancer-relevant networks associated with response to immunotherapy
ConclusionThe IgSF Interactome represents the first map of receptor-ligand interactions in humans, providing a framework for understanding the functional organization of the surfaceome during homeostasis and disease, and ultimately informing therapeutic development.Legal entity responsible for the studyGenentech, Inc.FundingGenentech, Inc.DisclosureN. Martinez-Martin: Shareholder / Stockholder / Stock options: Roche. E. Verschueren: Shareholder / Stockholder / Stock options: Roche. B. Husain: Shareholder / Stockholder / Stock options: Roche. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
